Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-11F8 plus modified FOLFOX-6 in untreated advanced or metastatic colorectal cancer
2006-003147-23Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2007
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of necitumumab, oxaliplatin, folinic acid and fluorouracil in colorectal cancer (CRC), sponsored by Eli Lilly and Company. Primary endpoint: Overall response rate. Started Mar 2007; status: completed.
02
Drugs
necitumumaboxaliplatinfolinic acidfluorouracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2006-003147-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003147-23.